Eesti - eesti - Ravimiamet

krka d.d. novo mesto - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - erlotiniib - õhukese polümeerikattega tablett - 25mg 30tk

Eesti - eesti - Ravimiamet

sia elvim - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 2.5ml 1tk

Eesti - eesti - Ravimiamet

santen oy - timolool+tafluprost - silmatilgad, lahus - 5mg+15mcg 1ml 7ml 1tk; 5mg+15mcg 1ml 3ml 3tk; 5mg+15mcg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

laboratoires thea - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 6ml 1tk; 5mg+50mcg 1ml 2.5ml 1tk

Eesti - eesti - Ravimiamet

first pharma oÜ - atsitretiin - kõvakapsel - 10mg 30tk

Eesti - eesti - Ravimiamet

ideal trade links uab - atsitretiin - kõvakapsel - 10mg 30tk; 10mg 100tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastilised ained - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic kasvajad, kastreerimine-vastupidavad - terapeutilised radiofarmatseutilised ühendid - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Eesti - eesti - Ravimiamet

santen oy - retinool+dekspantenool - silmasalv - 20rÜ+20mg 1g 3.5g 1tk